GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » YoY EPS Growth

Hepion Pharmaceuticals (FRA:336) YoY EPS Growth : 100.00% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Hepion Pharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2024 was 100.00%.

Hepion Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €0.00.


Hepion Pharmaceuticals YoY EPS Growth Historical Data

The historical data trend for Hepion Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals YoY EPS Growth Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.57 68.61 75.90 -33.90 100.00

Hepion Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -96.61 31.21 -13.48 100.00 100.00

Hepion Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Hepion Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(0--11.139)/ | -11.139 |
=100.00 %

Hepion Pharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(0--3.25)/ | -3.25 |
=100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hepion Pharmaceuticals YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (FRA:336) Business Description

Traded in Other Exchanges
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines